HANALL BIOPHARMA CO.,LTD
Financials
Valuation Metrics
HANALL BIOPHARMA CO.,LTD's Market Cap is ₩2.0T. At end of 2025 it was ₩2.3T. Ranked #198 of 2,410 in KR market (top 8%), #162 of 779 on KOSPI (top 21%), #17 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 7%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.96T KRW | KR#198/2,410 Sec#17/231 |
| Revenue | 162.66B KRW | KR#1,132/2,410 Sec#67/231 |
| Net Income | -24.90B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 240.51B KRW | KR#1,168/2,410 Sec#82/231 |
| Net Assets | 161.63B KRW | KR#1,088/2,410 Sec#77/231 |
| Employees | 318 | KR#755/2,410 Sec#65/231 |
| Value | ||
| P/B | 12.14x | KR#2,377/2,410 Sec#217/231 |
| P/S | 12.06x | KR#2,296/2,410 Sec#171/231 |
| EV/EBITDA | 414.22x | KR#1,549/2,410 Sec#110/231 |
| FCF Yield | -0.17% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -15.41% | KR#2,022/2,410 Sec#154/231 |
| ROA | -10.35% | KR#2,107/2,410 Sec#161/231 |
| Op. Margin | 2.93% | KR#1,258/2,410 Sec#91/231 |
| Revenue Growth | 8.38% | KR#985/2,410 Sec#97/231 |
| Earnings Growth | -1215.12% | KR#1,328/2,410 Sec#95/231 |
| Financial Health | ||
| Debt Ratio | 48.81% | KR#941/2,410 Sec#107/231 |
| Total Debt | 44.09B KRW | KR#1,049/2,410 Sec#72/231 |
| FCF | -3.29B KRW | KR#1,404/2,410 Sec#112/231 |
| Cash | 30.20B KRW | KR#1,008/2,410 Sec#69/231 |
| Current Ratio | 1.49x | KR#1,204/2,410 Sec#130/231 |
| Net Debt/EBITDA | 2.91x | KR#907/2,410 Sec#66/231 |
| Performance | ||
| 1Y Return | -9.30% | KR#400/2,410 Sec#24/231 |
| 1M Return | -18.55% | KR#1,645/2,410 Sec#162/231 |
| From 52W High | -48.56% | KR#1,067/2,410 Sec#80/231 |
| 1Y MDD | -46.96% | KR#829/2,410 Sec#65/231 |
| Trading | ||
| Volume | 98,460 shares | KR#652/2,410 Sec#68/231 |
| Trading Value | 3.70B KRW | KR#326/2,410 Sec#32/231 |
| Foreign Own. | 3.92% | KR#1,066/2,410 Sec#96/231 |
| Per Share | ||
| EPS | -477 KRW | KR—/2,410 Sec—/231 |
| BPS | 3,094 KRW | KR#1,853/2,410 Sec#139/231 |
Company Info
Hanall Biopharma is a pharmaceutical company established in 1973 and listed on the Korea Exchange in 1989. It manages overseas clinical trials and licensing for new drugs through its U.S. subsidiary, HPI. The company manufactures and sells over 160 pharmaceutical products for endocrine, circulatory, and other systems, while researching diverse new drugs, including antibody-based therapies for autoimmune diseases. By strengthening its R&D infrastructure with First-in-Class biosimilar drug research, dedicated personnel, and expanded facilities, Hanall Biopharma is enhancing its global market competitiveness. It is headquartered in Daedeok-gu, Daejeon.